Kornimate/medical-research-clean huggingface dataset:
anti-ficolin-3 autoantibodies in lupus nephritis

Conditions: Lupus Erythematosus, Systemic

Summary: systemic lupus erythematosus (sle) is a chronic autoimmune disease characterized by the production of multiple autoantibodies. antibodies against ficolin-3 were previously identified in the sera of some sle patients, but their prevalence and significance have not been yet investigated. the aims of this study were to determine the prevalence of anti-ficolin-3 antibodies among sle patients and to investigate their potential as diagnostic and/or prognostic biomarkers in sle. in this retrospective study, clinical data were obtained from medical files and blood samples were selected from preexisting biological collection. sle patients (n=165) were informed and did not objected, they were matched to healthy controls (n=48). disease activity was determined according to the sledai score. anti-ficolin-3, anti-dsdna and anti-c1q antibodies levels were measured in sera by elisa. first, a highly significant difference was found in the anti-ficolin-3 levels between sle patients and healthy subjects. anti-ficolin-3 antibodies were detected as positive in 58 of 165 (35%) sle patients. the titer of anti-ficolin-3 antibodies was correlated with the sledai score (p\<0.0001). the presence of anti-ficolin-3 antibodies was associated with anti-c1q and anti-dsdna antibodies. regarding associations with clinical manifestations, only the presence of active lupus nephritis was significantly associated with the presence of anti-ficolin-3 antibodies (p=0.0001). this association with renal involvement was higher with anti-ficolin-3 antibodies than with other auto-antibodies. interestingly, the combination of anti-ficolin-3 and anti-c1q antibodies demonstrated higher specificity than any other traditional biomarker. these results suggest that anti-ficolin-3 could be useful for the diagnosis of active nephritis in sle patients.

for this retrospective study, a brief summary should be enough.

Eligibility criteria:
165 sle patients inclusion criteria: * age: ≥ 18 years old * patients with lupus diagnostic criteria (acr1997) exclusion criteria: * pregnant women * patient with known evolutive cancer 48 healthy patients matched in age and sex with one or several sle patients

Keywords: ficolin-3 anti-ficolin-3 antibodies lupus nephritis lupus erythematosus, systemic biomarker
role of glycation and inflammation in acute ischemic heart disease

Conditions: Myocardial Infarction; Glycation End Products, Advanced; Inflammation; Heart Injuries; Heart Inflammation

Summary: this study requires the consecutive enrollment of 60 patients following the first event of acute myocardial infarction, evaluating b-cell activating factor (baff) and methylglyoxal (mgo) levels in the acute setting (pre-reperfusion) and 3 months after reperfusion.

this study requires the consecutive enrollment of 60 patients at admission for first acute myocardial infarction. at enrollment, before reperfusion, a blood sample is obtained to measure b-cell activating factor (baff) and methylglyoxal (mgo) levels in the acute setting. this measure is then repeated at follow-up visit 3 months after reperfusion. the aim of the study is to identify specific subsets of patients and evaluate biomarkers variations.

Eligibility criteria:
inclusion criteria: * hospitalization for first myocardial infarction (stemi or nstemi) * age between 18 and 80 exclusion criteria: * uncompensated t2dm (hba1c \>53mmol/mol) * use of anti-cd20 treatment * chronic anti-inflammatory treatment for autoimmune disease (i.e. dmards, high dose fans, cortisonic drugs)

Keywords: ages baff myocardial infarction
physical activity, exercise capacity and coronavirus phobia of adult cystic fibrosis patients during covid-19 pandemic

Conditions: Cystic Fibrosis

Summary: the purpose of this study was to evaluate physical activity, exercise capacity, quality of life, cognitive status level and coronavirus phobia level of adult cystic fibrosis patients and compare with the findings of healthy subjects with teleconference during covid-19 pandemic.

this study will be participated adult with cystic fibrosis and healthy individuals. demographic information of individuals will be recorded in online video conference. physical activity, exercise capacity and cognitive function levels will be measured during video conferencing.then, the physical activity level, coronavirus phobia and quality of life of the participants will be evaluated subjectively with questionnaires through the google forms.

Eligibility criteria:
inclusion criteria: * being over 18 years old having the ability to access the internet through a device (computer or mobile device) that enables video conferencing giving consent on a voluntary basis exclusion criteria: * severe comorbidity that limits mobilization or physical activity(orthopedic, cardiac or neurological condition) pregnancy
health tourism in bariatric surgery

Conditions: Anxiety

Summary: the aim of the study is to examine whether patients who come to our country for bariatric surgery via health tourism have any concerns during this process, and if they do, to determine the level of their concerns through psychometric tests, to determine the reasons for their concerns (is it related to travel, going to another country, hospital, surgery, etc.) and whether their concerns decrease after the surgery.


Eligibility criteria:
inclusion criteria: * patients who came to our country through health tourism * patients with indications for bariatric surgery * patients over the age of 18 exclusion criteria: * patients under 18 years of age * patients with psychiatric, neurological diseases or mental retardation that prevent them from completing psychometric tests * patients with bariatric surgery indications other than health tourism * patients who do not agree to participate in the study
effect of dapagliflozin on myocardial and renal function following aortic valve stenosis intervention

Conditions: Aortic Stenosis; Left Ventricle Hypertrophied

Summary: randomized, double-blinded, placebo-controlled study in as patients with subclinical or clinical heart failure undergoing treatment with tavr.

this is a randomized, double-blinded, placebo-controlled study in as patients with subclinical or clinical heart failure undergoing treatment with tavr. it evaluates the effect of dapagliflozin versus placebo, given once daily in addition to background standard medical therapy. patients who are scheduled for tavr at aarhus university hospital (auh) will be informed about the project and invited to participate if they fulfill the inclusion criteria prior to the tavr procedure. patients will be randomized 1:1 in blocks of 6 patients to either dapagliflozin 10 mg daily or placebo within 1 months prior to the scheduled tavr therapy. the total treatment period is 13 months with 6 scheduled outpatient clinic visits at baseline (before tavr) and at 1, 3, 6, 9, 12 months after tavr. cardiac magnetic resonance imaging (cmri) is performed at baseline and 12 months follow-up. echocardiography is performed at baseline, 1- and 12 months. 24-hour ambulatory blood pressure is measured at baseline and 12-months post-tavr. clinical status, hf questionnaire and blood samples will be performed at each visit. drug accountability and adherence to the protocol is evaluated at each visit. a sub study in 40 of the included patients (20 treated with dapagliflozin and 20 placebo) is planned. this will include additional endomyocardial biopsies taken at baseline and 12-months follow-up for high resolution respirometry (mitochondrial function) and electron microscopy (mitochondrial structure and interstitial fibrosis) supplemented by right heart catherization (rhc) for hemodynamic assessment.

Eligibility criteria:
inclusion criteria: 1. signed informed consent 2. scheduled tavr for significant symptomatic as according to current guidelines 3. age ≥ 18 years and \< 85 years. 4. \* * lvef ≥ 40% and ≤ 50 % or lvef ≥ 50% with at least one of the following: * lv gls ≤ 15% by tte * lv septum or posterior wall thickness ≥ 12mm by tte or lv mass index ≥108/131 g/m2 for females/males (mild lvh) * lvef ≥ 50 % and nt-probnp \> 600/900 ng/l (sinus rhythm/atrial fibrillation) 5. egfr \> 30 ml/min/1.73 m2 exclusion criteria: 1. medically treated type 1 or type 2 diabetes mellitus 2. ongoing treatment with an sglt2-inhibitor or intolerance to sglt2-inhibitors 3. life expectancy \< 12 months 4. symptomatic hypotension or persistent sbp \< 100 mmhg 5. contraindications to cmri 6. hf due to restrictive or infiltrative cardiomyopathy, active myocarditis, constrictive pericarditis or hypertrophic obstructive cardiomyopathy 7. additional other untreated severe valvular disease 8. liver failure 9. women who are pregnant or plan to be within the study period. 10. allergy to any substance in the project medicine, both placebo and active medicine. 11. previous renal transplantation. 12. chronic dialysis treatment.
dynamic changes of serum hbv rna in chronic hepatitis b patients

Conditions: Chronic Hepatitis B Patients

Summary: some patients with low-level viremia (llv) are also likely to develop hepatocellular carcinoma (hcc) or other liver diseases. the relationship between hbv rna levels and fibrosis in patients with hbv dna negative or llv is still lacking evidence. the purpose of this study is to observe the differences in hbv rna levels and their association with efficacy in hbv dna negative or llv patients. investigators conduct the prospective, single-center, non-randomized, observational clinical study. a total of 100 chronic hepatitis b (chb) patients who receive antiviral therapy with nucleoside (acid) analogues for 1-3 years will be enrolled. the enrolled patients will be followed up five times to collect clinical data and record adverse events (at baseline, week 12, week 24, week 36 and week 48, respectively).


Eligibility criteria:
inclusion criteria: * 1.18 years old or above and the gender is not limited; * 2. patients who receive antiviral therapy with nucleoside (acid) analogues for 1-3 years ; * 3. patients with hbv dna negative (hbv dna\<20 iu/ml) or llv（hbv dna 20-2000 iu/ml） * 4. good compliance and voluntary signing of informed consent. exclusion criteria: * 1. patients with decompensated cirrhosis; * 2. patients co-infection with other viruses, such as hepatitis a virus, hepatitis c virus, hepatitis d virus, hepatitis e virus, hiv virus, etc.; * 3. patients with significant renal, cardiovascular, pulmonary, or neurological disease; * 4. patients have active or suspected malignancy or history of malignancy; * 5. patients who were identified not appropriate for the study by investigators.
study of high-dose pulse administration dn-101 (calcitriol) in patients with myelodysplastic syndrome (mds)

Conditions: Myelodysplastic Syndrome

Summary: the purpose of this study is to determine the safety and efficacy of dn-101 (calcitriol) in patients with myelodysplastic syndrome who are dependent on repeat blood transfusions.

dn-101 is an experimental drug that has not been approved by the food and drug administration (fda). it is a newly formulated pill that contains high amounts of calcitriol, a naturally occurring hormone and the biologically active form of vitamin d. the natural vitamin d found in dairy products or in typical vitamin pills, must be chemically changed by the liver and kidney into calcitriol before it is biologically active. the body normally uses small amounts of calcitriol to regulate its blood calcium levels. however, for any possible therapeutic effect, mds patients require much higher levels of calcitriol than the body can produce from dietary vitamin d. dn-101 provides mds patients with high doses of calcitriol in a pill form. laboratory studies have demonstrated evidence supporting the use of calcitriol in mds. high dose calcitriol slows the growth of leukemic cells (cancerous cells) and increases the growth of normal bone marrow cells. some patients with mds may have low levels of calcitriol in their bone marrow. clinical study results in patients with mds have been mixed- some positive and some negative results. elevated calcium in the blood occurred frequently and prevented the use of higher, more potentially therapeutic doses. novacea tested a new formulation of calcitriol, dn-101, in a phase 1 study. in that study the maximum tolerated dose of dn-101 that did not cause high blood calcium levels when given weekly for several months was determined. that dose is within the range that is potentially therapeutic for mds patients and will be used in this mds study. the purposes of this study are to determine if hdpa dn-101 treatment: * increases the number of red blood cells, white blood cells, and platelets in the blood * reduces the number of blood transfusions * reduces the number of serious infections requiring antibiotics * reduces the number of serious bleeding events * improves fatigue

Eligibility criteria:
* diagnosis of low or intermediate-1 risk mds * dependent on monthly blood transfusions * no cancer within the last 5 years (cured skin cancer is allowed) * no heart attack or stroke within the last 6 months * no kidney stones within the last 5 years

Keywords: myelodysplastic syndrome mds
effects of adjunctive photodynamic therapy to non-surgical periodontal treatment in patients with generalized aggressive periodontitis

Conditions: Generalized Aggressive Periodontitis

Summary: generalized aggressive periodontitis (gagp) is a distinct type of periodontal disease characterized by rapid loss of attachment and alveolar bone occuring in young individuals. photodynamic therapy (pdt) was introduced in periodontology as an adjunctive approach to non-surgical periodontal treatment (npt) in periodontitis patients. in this trial, it was aimed that to evaluate the clinical and microbiological effects of adjunctive pdt to npt in patients with gagp. in this prospective controlled clinical study, 24 systemically healthy, non-smoking subjects with gagp were enrolled. subjects were randomly assigned to a control group (n=12) treated with npt only or to a test group (n=12) treated with npt and pdt. plaque index, sulcus bleeding index (sbi), pocket depth (pd), relative attachment level, gingival recession, mobility were recorded at baseline and on day 63. microbiological samples were obtained fom the sites with pd ≥5 mm at the same time points and evaluated for aggregatibacter actinomycetemcomitans, porphyromonas gingivalis, prevotella intermedia, tannerella forsythia and treponema denticola using micro-ident test.


Eligibility criteria:
inclusion criteria: * systemically healthy, * non-smoker * not received any periodontal treatment within the last 6 months * no antibiotics, anti-inflammatory drugs or any other medication taken within the last 6 months * consent to participate in the study exclusion criteria: * any systemic disease (i.e. diabetes mellitus, hiv infection) that might influence the prognosis of periodontal disease and outcome of the treatment * any medical condition that required antibiotic prophylaxis before the treatment * smoking * pregnancy and lactation * ingestion of antibiotics, anti-inflammatory drugs or any other medication during study period * any physical limitations or restrictions that might preclude normal oral hygiene procedures
morbi-mortality by covid-19 among homeless people in marseille: a cohort study

Conditions: Homeless

Summary: covid/homeless is a prospective observational cohort study of homeless people to determine the impact of the sars-cov-2 epidemic on this population. the cohort aims for exhaustiveness for the city of marseille, being based on the active files of the partner teams, namely the four emergency shelters of marseille and 12 outreach teams (including one specialized in psychiatry, three specialized in addictions, and three working in squats and shantytowns). aims of this cohort include to identify of the prognostic factors of morbi-mortality of homeless people by covid-19, and therefore to propose appropriate management strategies.


Eligibility criteria:
inclusion criteria: * living in the city of marseille * being homeless * be over 18 years of age exclusion criteria: * persons under guardianship * persons who refused to sign the research consent
sowing the seeds of confidence: brief online group parenting programme for anxious parents of 1-3 year olds

Conditions: Anxiety; Parenting

Summary: to pilot a brief group early intervention aimed at reducing or preventing the intergenerational transmission of anxiety, with parents whose child is between 12 and 47 months. to explore feasibility and acceptability of such an intervention with this population.

all participants will attend two group sessions of 'psychoeducation' (psychologically informed information about the topic of transmitting anxiety) and cognitive-behavioural strategies aimed at reducing the transmission of anxiety from parent to young child. the two sessions will be delivered online via microsoft teams, last 2 hours each and will run one week apart. outcome and acceptability measures will be collected before, immediately after, and 6 weeks after the intervention. feasibility data (e.g. drop-out rate) will be recorded.

Eligibility criteria:
inclusion criteria: * current or recent (within 2 years) primary diagnosis of anxiety disorder or self-report of clinically impairing anxiety problem within last 2 years, * parent of child aged 12-47 months at time of intervention, * access to an internet connection and smart phone/computer will be required to take part, * male or female, * resident in england, * and over the age of 18 exclusion criteria: * current severe co-morbid diagnoses, e.g. psychosis or acute suicidal risk (as the nature of the intervention is brief and in a group, the level of support needed to keep those with severe mental health disorders safe will not be available), * current alcohol or drugs misuse
focused lung ultrasound: a prospective cohort study in general practice

Conditions: Ultrasonography; Respiratory Tract Infections; Pneumonia; General Practice

Summary: this is a prospective cohort study that describes focused lung ultrasound (flus) findings in patients presenting with symptoms of an acute lower respiratory tract infection (lrti) in general practice in denmark. ten general practitioners (gps) will perform flus in addition to their usual care of adults presenting with symptoms of an acute lrti where the gp suspects a community-acquired pneumonia (cap). eligible patients will consecutively be invited to participate during a two months' study period until each gp has included a total of ten patients. the gps will register information about patients including age, gender, symptoms, clinical findings, results of any point-of-care test performed, if antibiotic treatment was prescribed and they will register information on flus performance and findings.


Eligibility criteria:
inclusion criteria (gps): gps who use pocus (point-of-care ultrasound) at least once a week in general practice or out-of-hour services. inclusion criteria (patients): patients aged ≥ 18 years with acute cough (\< 28 days) and at least one other symptom of an acute lrti and where the gp suspects cap. exclusion criteria (patients): * previous antibiotic prescription for the current episode of acute lrti. * patients not listed with the gp (no medical record available). * the patient is not capable of understanding and signing informed consent. * the patient does not wish to participate in the study.
safety and efficacy study of omniwave endovascular system to treat deep vein thrombosis

Conditions: Deep Vein Thrombosis

Summary: this is a prospective, multi-center single arm registry to assess the use of the omniwave endovascular system in subjects presenting with either lower or upper extremity acute (symptoms have been present for greater than or equal to 14 days) dvt.


Eligibility criteria:
inclusion criteria: * dvt confirmed by venographic and ultrasound imaging, which has been symptomatic for a maximum of 14 days, or diagnosed within past 14 days defined as either first episode (no prior history in affected segment), or recurrent episode. * written informed consent * agreement to comply with follow up requirements exclusion criteria: * known r-l shunt, pulmonary a-v malformation * excessive tortuosity and/or sharp angulation in target treatment zone * isolated calf vein thrombosis * isolated dvt in veins peripheral to axillary vein * thrombus in peripheral vessel smaller than 5 mm * target treatment zone cannot be adequately accessed within the 100 cm working length of device

Keywords: dvt peripheral vascular disease venous thrombosis deep vein thrombosis
postprandial effects of a high potassium meal

Conditions: Hypertension

Summary: the investigators aim to evaluate the acute effects of potassium supplementation achieved by ingestion of potassium rich food, on vascular health.

many studies have shown that an increase in potassium through the diet or through potassium pills helps to lower blood pressure. also, the amount of oral potassium taken can improve how well the participants blood vessels work. these studies have focused on potassium given in the form of a pill. the investigators are interested in the effect of potassium consumed through food sources and how it will effect arterial health and blood pressure. the world health organization (who) recommends a k⁺ intake of at least 3510 mg/day from food for adults, excluding those with impaired k⁺ excretion. in this study the investigators aim to provide approximately 75% (approximately 2000 mg) of the total daily recommended intake for potassium in one meal. the investigators do not know whether dietary potassium (not pill form) will acutely improve the arterial health and if it will cause a decrease in blood pressure. the investigators hypothesis to see an improvement in vascular function following a high potassium meal compared to a low potassium meal.

Eligibility criteria:
inclusion criteria: * 18-80 years * normal sinus rhythm * a diagnosis of hypertension on medical therapy with an ambulatory systolic blood pressure \<160 mmhg and diastolic blood pressure \<90 mmhg, or a diagnosis of stable coronary artery disease exclusion criteria: * recent hospital admission due to an cardiovascular events * serum k+ concentration \>5.0 mmol/l * current smoking * women who are pregnant * diabetic patients - patients receiving insulin therapy * glomerular filtration rate \< 90mls/min/1.73m2 * on loop diuretic therapy * food allergies and/or intolerance to meal items

Keywords: dietary potassium